Entest BioMedical Announces Approval of Its Protocols for ImenVax(TM) Safety Study by CRO's Internal Animal Care and Use Committee
Company Has Begun Patient Profile Review in Preparation For Enrollments in ImenVax(TM) Safety Study
SAN DIEGO, CA, Nov 17, 2010 (MARKETWIRE via COMTEX) -- Entest BioMedical Inc. announced today it has received approval from its Contract Research Organization's (CRO) Internal Animal Care and Use Committee on the Company's protocols necessary for proceeding with Entest's ImenVax(TM) Safety Study. This study will involve the use of the Company's ImenVax(TM) immuno-therapeutic canine cancer vaccine on 10 dogs. The Company expects the outcome to demonstrate that ImenVax(TM) is safe to use in the treatment of dogs with cancer. Additionally, the Company anticipates it will gather data that supports efficacy in this form of treatment for dogs with cancer.
Entest BioMedical's Chairman & CEO David Koos commented, "This represents a major event for us. Clearing our protocols is the first milestone towards having a viable treatment for canine cancer. Currently, we have begun reviewing patient profiles to prepare for the study's enrollment of dogs that will participate in this treatment. Our goal is to provide a safe treatment for dogs with cancer that is minimally invasive. I have two basset hounds and want to protect their future as well as the future of other pet owners' pets."
A spokesperson for the Company stated that the Company intends to move forward as quickly as possible.
About Entest BioMedical Inc.:
Entest BioMedical Inc. is a developer of veterinary medicines that harness the animal's own reparative / immunological mechanisms. The company's products include an immuno-therapeutic cancer vaccine for canines (ImenVax(TM)). The company's immuno-therapeutic cancer vaccine utilizes an encapsulation device as the vaccine delivery system and requires a simple implant procedure that is less invasive than major surgery associated with cancer and is not expected to result in the deleterious side effects associated with chemotherapy and radiation therapy.
This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
David R. Koos
Entest BioMedical Inc.
Chairman & CEO